“`html
Development and Characterisation of a New Patient-Derived Xenograft Model of AR-Negative Metastatic Castration-Resistant Prostate Cancer
Key Points:
- Prostate cancer is evolving, leading to more treatment-induced neuroendocrine and double-negative prostate cancer cases.
- These subtypes are resistant to standard treatments, making it challenging to find effective therapies.
- The CU-PC01 PDX model represents AR-negative mCRPC with specific genetic variants and lacks classic NE markers, making it a valuable tool for studying this disease.
- Ex vivo and in vivo studies show that CU-PC01 tumors are resistant to standard treatments but initially sensitive to PARP inhibition with olaparib.
- This model provides an opportunity to explore new treatment options for this difficult-to-treat disease.
“`
